Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Siemens introduces new Sysmex CS-2500 mid-volume coagulation analyzer

MDBR Staff Writer Published 04 August 2016

Siemens Healthineers Laboratory Diagnostics business has introduced a mid-volume, fully-automated coagulation analyzer with smartly-designed PSI technology.

The Sysmex CS-2500 System features multiwavelength scanning and PSI technologies, which enable labs to provide quality test results and achieve cost-effective method consolidation.

The system can be used for primary-tube sample-volume checks, clog detection and assay-based preanalytical sample-quality checks for hemolysis, icterus and lipemia (HIL) interference.

It can also be used for automated mixing studies, automated platelet aggregation and clot waveform analysis (CWA).

It is said to deliver extended walkaway time to streamline workflow with an onboard capacity of up to 3,000 tests and 40 reagents.

The new coagulation analyzer allows hemostasis laboratories to standardize testing results across multiple Sysmex CS and CA hemostasis systems.

Siemens Healthineers laboratory diagnostics president Franz Walt said: “Labs today are challenged to increase their output without sacrificing the accuracy or reliability of their results.

“The increased operational efficiency and uninterrupted workflow delivered by the Sysmex CS-5100 and CS-2500 Systems provide our customers with the confidence, consistency and increased capacity they need to deliver timely and accurate hemostasis test results.”

Lab Alliance of Central New York has installed the high-volume Sysmex CS-5100 system, which is available in all major markets including the US.

Laboratory Alliance of Central New York hematology manager Anne Chamberlain said: “The Sysmex CS systems and the services offered by Siemens Healthineers are the perfect fit for our laboratory and laboratory networks similar to ours.”